Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech (NASDAQ/TASE: PPBT) has announced promising new data for its CAPTN-3 tri-specific antibody IM1240 in collaboration with Mount Sinai. The research, led by Dr. Amir Horowitz, demonstrated successful tumor cell death in treatment-resistant head and neck cancer biopsies.
Key findings show synergistic effects between NK and T cell engager arms of IM1240, and analysis of 26,000 human transcriptomes validates the antibody's design targeting 5T4 and NKG2A. The company plans to submit an IND application in 2026 for first-in-human clinical trials.
The research spans multiple resistant cancers including NSCLC, HNSCC, and bladder cancer. IM1240's unique design offers potentially safer checkpoint inhibition compared to existing therapies, particularly through its selective NKG2A targeting.
Purple Biotech (NASDAQ/TASE: PPBT) has announced the development of IM1305, its second CAPTN-3 tri-specific antibody targeting TROP2. The novel antibody combines a masked anti-CD3 arm, an anti-NKG2A arm, and an anti-TROP2 arm to target solid tumors.
Preclinical results show sustained tumor regression in human triple negative breast cancer (TNBC) mouse models, with significant cell death induction across multiple tumor types at low doses. The antibody's unique design includes a cleavable cap that activates specifically in the tumor microenvironment, potentially reducing off-target effects.
TROP2, the target protein, is widely expressed in major solid tumors including breast, lung, gastrointestinal, and ovarian cancers. The company plans to leverage its platform technology to accelerate development and explore partnering opportunities.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Gil Efron will participate in a fireside chat on September 10, 2025, at 11:30 AM ET. The company will also be available for one-on-one investor meetings through the conference portal.
Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2025 financial results and significant clinical progress across its pipeline. The company highlighted positive data from its CAPTN-3 tri-specific antibody platform at EACR 2025, with plans to submit an IND for IM1240 in 2026.
Key clinical achievements include statistically significant Phase 2 results for CM24 in pancreatic cancer, showing up to 78% reduction in death risk and 37.5% ORR in biomarker-selected patients. The company also initiated a Phase 2 study of NT219 in head and neck cancer.
Financial highlights include reduced R&D expenses to $0.6M (down 76.9% YoY), operating loss of $1.2M (down 64.3% YoY), and cash position of $5.6M, providing runway into Q3 2026.
Purple Biotech (NASDAQ/TASE: PPBT) CEO Gil Efron shared significant progress in their clinical pipeline during H1 2025. The company's lead candidate CM24 showed promising Phase 2 results in pancreatic cancer (PDAC), with notably higher objective response rates in biomarker-enriched subgroups (37.5% vs 0% control).
Key developments include positive data from the CAPTN-3 platform presented at EACR 2025, featuring novel capping technology, and advancement of NT219 into Phase 2 combination studies. The company plans to initiate a biomarker-driven Phase 2b study for CM24 and expects to submit an IND for CAPTN-3's first candidate in 2026.
Purple Biotech maintains a cash runway extending into mid-2026, though additional funding will be required for future clinical studies.
Purple Biotech (NASDAQ/TASE: PPBT) has appointed Shai Lankry as its new Chief Financial Officer. Lankry brings over 20 years of financial leadership experience in biotech and healthcare sectors. His notable career includes serving as CFO of Gamida Cell Ltd. (2018-2023), Finance Director at West Pharmaceutical Services (2016-2018), and CFO at MacroCure Ltd. (2013-2017), where he successfully led a U.S. IPO and M&A transaction with Leap Therapeutics.
Most recently, Lankry operated his own consulting firm, LS Consulting Services. He holds an M.B.A. in Finance from Tel-Aviv University and is a licensed Israeli CPA. The appointment comes as Purple Biotech, a clinical-stage company developing first-in-class therapies for tumor immune evasion and drug resistance, advances its pipeline into late-stage trials.